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Although in different groups, the coronaviruses severe acute respiratory syndrome-coronavirus
(SARS-CoV) and NL63 use the same receptor, angiotensin converting enzyme (ACE)-2, for entry
into the host cell. Despite this common receptor, the consequence of entry is very different; severe
respiratory distress in the case of SARS-CoV but frequently only a mild respiratory infection
for NL63. Using a wholly recombinant system, we have investigated the ability of each virus
receptor-binding protein, spike or S protein, to bind to ACE-2 in solution and on the cell surface.
In both assays, we find that the NL63 S protein has a weaker interaction with ACE-2 than the
SARS-CoV S protein, particularly in solution binding, but the residues required for contact are
similar. We also confirm that the ACE-2-binding site of NL63 S lies between residues 190 and
739. A lower-affinity interaction with ACE-2 might partly explain the different pathological
consequences of infection by SARS-CoV and NL63.
Severe acute respiratory syndrome (SARS) and NL63
coronaviruses (CoV) are two new members of the family
Coronaviridae that have received considerable attention
since their recent discovery (Drosten et al., 2003; Kuiken
et al., 2003; Li et al., 2003; Pyrc et al., 2007; Sloots et al.,
2008; van der Hoek et al., 2004). Infection by SARS-CoV
causes severe acute respiratory syndrome with high levels
of morbidity and mortality (Drosten et al., 2003; Feng &
Gao, 2007; Kuiken et al., 2003), while infection by NL63
rarely requires hospitalization despite being commonly
associated with lower respiratory tract infection and croup
(van der Hoek, 2007; van der Hoek et al., 2005; Wu et al.,
2008). Both viruses use angiotensin converting enzyme
(ACE)-2 as the viral receptor (Hofmann et al., 2005; Li et
al., 2003), raising the interesting possibility that the
difference in pathology is (in part) the result of differential
receptor engagement. Virus-mediated downregulation of
ACE-2 has been suggested to underlie the pathology of
SARS-CoV infection (Imai et al., 2005; Kuba et al., 2005)
and it is unclear why this should not also be the case for
NL63. Following engagement with ACE-2, the cellular
pathways of internalization of the two viruses also appear
to be different with SARS-CoV requiring the presence of
the lysosomal cysteine protease cathepsin L to infect
susceptible cells, while NL63 has no such requirement
(Huang et al., 2006). These data suggest that although both
viruses utilize ACE-2 as the receptor, the consequences of
receptor binding differ, although the reasons for this
remain unclear. Using NL63 pseudotyping and soluble S
binding to ACE-2-expressing mammalian cells, Hofmann
et al. (2005) showed that while ACE-2 leads to efficient
NL63 S-mediated entry, the binding of NL63 S was
apparently lower than that of SARS-CoV S. They later
suggested that this may be the consequence of NL63 S
protein binding to a different region of ACE-2 (Hofmann
et al., 2006). In contrast, following the definition of a
minimum receptor-binding domain (RBD) within NL63 S,
residues 301–749, Li et al. (2007) showed that incubation
of a tagged form of the RBD with cell lines expressing a
number of natural and synthetic ACE-2 variants indicated
that the ACE-2 contact residues critical for binding both
SARS-CoV and NL63 S overlap (Li et al., 2007). The
binding site for both viruses is distinct from the active site
of the enzyme (Guy et al., 2005; Towler et al., 2004),
consistent with the fact that treatment of ACE-2-bearing
cells with MLN-4760, a potent ACE-2 inhibitor, has no
effect on S–RBD interaction or virus entry (Li et al.,
2005b). However, while confirming that full-length SARS-
CoV S appeared to bind to ACE-2-expressing cells more
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efficient at competing with NL63-mediated pseudotype
entry than competition with SARS-CoV-mediated entry
(IC50 of ~200 ng ml
21 for NL63 compared with
~50 ng ml
21 for SARS-CoV) (Li et al., 2007). A recent
report suggests that the minimum NL63 RBD lies between
residues 476 and 616 and that, expressed alone, the binding
affinity with ACE-2 reaches that observed for SARS-CoV S
(Lin et al., 2008). Here, using a wholly recombinant system
that precludes the involvement of any other cell surface
factor present on mammalian cells, such as lectins [e.g. DC-
SIGN (Marzi et al., 2004)], we show that the soluble forms
of both SARS-CoV and NL63 S protein bind soluble ACE-2
in vitro with substantially different affinity. Discrepant
binding is maintained but reduced when the S proteins are
displayed on the cell surface where avidity may compensate
for inherent affinity changes. We confirm that ACE-2
residues shown to be critical for SARS-CoV S binding also
abolish NL63 S binding and that the binding of NL63 S
does not involve its unique amino-terminal sequence.
Differences in the affinity of ACE-2 interaction with the
different CoV S proteins are therefore independent of assay
format and may underlie the different pathological
outcomes of infection.
To investigate CoV S protein binding to ACE-2 in a unified
format, we produced soluble and cell-bound versions of the
two S proteins through the use of baculovirus expression
vectors designed for secretion of proteins as Fc-tagged
fusion proteins (Chen et al., 2007) or, separately, displayed
on the insect cell surface following tagging with the VSV G
protein transmembrane (TM) domain (Chapple & Jones,
2002) (see Supplementary Fig. S1, available in JGV Online).
The vectors are isogenic except for the tags employed and
lead to the abundant expression of the target glycoproteins
in the cells and supernatant for both the SARS-CoV and
NL63 S proteins and subdomains thereof (Fig. 1). In
addition, we produced a secreted form of ACE-2 fused to
green fluorescent protein (GFP) to provide a ligand with an
alternate tag for the detection of ligand binding. In order to
validate the interaction assays used, we produced two
variants of the SARS-CoV S1 domain with alanine
substitutions at arginine 426 (R426A) or asparagine 473
(N473A), known to reduce the affinity of SARS-CoV S1
interaction with ACE-2 (Chakraborti et al., 2005). In
addition, we introduced two alanine substitutions in the
ACE-2 sequence at tyrosine 41 (Y41A) and lysine 353
(K353A), both of which have been mapped as important
for the interaction of ACE-2 with SARS-CoV S (Li et al.,
2005b). With these differentially tagged and mutated
potential ligands, we assessed the interaction of the CoV
S proteins with ACE-2 by ELISA, pull-down and flow
cytometry assays.
Preliminary ELISAs capturing ACE-2-GFP to the plate,
followed by incubation with the various Fc-tagged forms of
S protein and detection with an anti-human Ig conjugate
showed detectable interaction with SARS-CoV S and S1,
but no interaction with either S1 R426A or N473A as
expected (data not shown). Ligand binding was equally
demonstrable in the alternate format of S capture followed
by ACE-2–GFP and an anti-GFP probe. However, at
equivalent concentrations of S protein, no interaction with
NL63 S or any of its derivatives was detected in either assay
format, suggesting an affinity of interaction for NL63 S
with ACE-2 in solution that is substantially lower than that
of SARS-CoV S. Supernatants containing Fc-tagged CoV S
proteins were concentrated by spin dialysis, the levels of S
protein present were normalized by quantitative Western
blot and equivalent amounts of Fc-tagged S proteins were
incubated with ACE-2–GFP in solution for 1 h at 21 uC.
Following pull-down of the Fc components with protein A
conjugated to Sepharose beads, the recovered contents
were resolved by SDS-PAGE and the presence of CoV S
proteins and GFP-tagged ACE-2 was detected by Western
blot using anti-human Ig and anti-GFP antibodies,
respectively. We observed that while SARS-CoV S and S1
pulled down ACE-2 effectively, NL63 S proteins pulled
down between 10- and 100-fold less ACE-2 on a weight-
for-weight basis (Fig. 2a). ACE-2 interaction was apparent
for NL63 S, NL63 S15–739 and NL63 S196–739 but not for
NL63 S15–195 (subscript numbers indicate the residues
contained within each fragment) confirming that the
unique 180 residue amino terminus of NL63 does not
bind ACE-2 (Hofmann et al., 2006; Li et al., 2007) (Fig. 2).
Using SARS-CoV S1 and the minimum NL63 binding
construct, NL63 S196–739, we tested the relative pull-down
of ACE-2 with substitutions at residues 41 and 353. SARS-
CoV S1 failed to interact significantly with ACE-2 Y41A
(~2%), it had reduced but demonstrable binding with
Fig. 1. Expression of SARS-CoV and NL63 S proteins using
recombinant baculoviruses. Western blots of expression at 2 days
p.i. with viruses encoding proteins either as Fc fusion proteins (a) or
followingfusiontotheVSVG TMdomain(b).In (a),supernatant was
probed with anti-human Ig; in (b), the cell pellet was probed with
anti-VSV G protein. Lanes: 1, SARS-CoV S; 2, SARS-CoV S1
(residues 19–713); 3, NL63 S; 4, NL63 S15–195; 5, NL63 S15–739;
6, NL63 S196–739. Molecular mass markers are indicated (kDa).
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(Fig. 2b). NL63 S196–739 also failed to effectively pull down
ACE-2 Y41A and did not pull down either ACE-2 K353A
or the double mutant (Y41A+K353A) (Fig. 2b). Together
these data show that NL63 S has a lower innate affinity for
ACE-2 when compared with SARS-CoV S, and confirm the
results of Li et al. (2007) which show that NL63 S and
SARS-CoV S bind an overlapping ACE-2 sequence.
However, this study demonstrated that the role of ACE-2
residue 353 was noticeably different. Substitution of the
resident lysine for alanine reduced, but did not abolish,
SARS-CoV S binding, while it effectively abolished binding
by NL63 S. In addition, as the end points in our constructs
differed somewhat from those published by Li et al. (2007),
our data reduced the carboxy-terminal boundary of the
NL63 S RBD in an analogous Fc-fusion protein configura-
tion from residue 749 to 739; however, this boundary is not
reducedasfarasresidue616asrecentlydescribedbyLinetal.
(2008). An affinity of interaction with ACE-2 by NL63 S of
10–100-fold less than that of SARS-CoV S would explain our
inability to obtain a sound Kd for the interaction by surface
plasmon resonance. The SARS-CoV S1 affinity with ACE-2
was 8.71610
28 M (Supplementary Fig. S2, available in JGV
Online), which is similar to published values (Li et al.,
2005b). However, the same assay format failed to record an
accurate Kd for the interaction of NL63 S with ACE-2.
To assess whether the low affinity of NL63 for ACE-2
might be partly compensated for by avidity effects of the S
proteins clustering on the viral surface, we used the same S
protein domains expressed as VSV G TM fusions on the
insect cell surface to examine binding with soluble ACE-2.
Using flow cytometry with insect cells expressing S proteins
at 2 days post-infection (p.i.), when expression levels were
saturating (Fig. 1), incubation of infected cells with an
excess of ACE-2–GFP resulted in a two- to threefold
difference in ACE-2 binding between SARS-CoV and NL63
S1 (Fig. 3a). When the range of NL63 S protein fragments
was assessed, ACE-2 binding was observed for all the S
derivatives, with the exception of the unique amino-
terminal domain S15–195 (Fig. 3b), which is in agreement
with the solution phase pull-down assays. When SARS-
CoV S1- and NL63 S19–739-decorated insect cells were
Fig. 2. Pull-downs of the various Fc-tagged S proteins after
incubation with ACE-2–GFP or ACE-2 mutants. Following SDS-
PAGE, the blots were probed with anti-human Ig to detect the S
proteins (Fc, upper panels) or anti-GFP to detect ACE-2 (GFP,
lower panels). (a) The ligand was ACE-2 wild-type. Samples in
lanes 1–5 are SARS-CoV S, SARS-CoV S1 (residues 19–713),
NL63 S, NL63 S15–195, NL63 S15–739, respectively. (b) The ligand
was wild-type ACE-2 (lanes 1 and 5), ACE-2 Y41A (lanes 2 and
6), ACE-2 K353A (lanes 3 and 7) or ACE-2 Y41A+K353A
(lanes 4 and 8). Samples are pull-downs with SARS-CoV S1
(lanes 1–4) and NL63 S196–739 (lanes 5–8). Molecular mass
markers are indicated (kDa).
Fig. 3. The interaction of CoV S proteins with
ACE-2 measured by flow cytometry. Insect
cells infected with recombinant baculoviruses
expressing the VSV G-tagged form of S
protein were used at 2 days p.i. and incubated
with either ACE-2 or ACE-2 mutants. (a) Direct
comparison between SARS-CoV S1 and the
NL63 equivalent incubated with wild-type
ACE-2. (b) Comparison between the different
fragments of NL63 S using wild-type ACE-2.
(c, d) Comparisons between SARS-CoV S1
(c) and NL63 S1 (d) incubated with ACE-2
mutants Y41A and K353A. Note the residual
shift by SARS-CoV S1 to K353A, which is not
apparent for NL63.
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binding was observed for both proteins; the relative reduction
in binding parallelled that seen in the pull-down assays.
Neither S protein bound the Y41A mutant significantly; there
was low residual binding by the K353A mutant to displayed
SARS-CoV S1 but no binding to displayed NL63 protein. We
conclude that multivalent presentationof the Sprotein onthe
cell surface retains the differential binding affinities shown by
solution-phase-binding for SARS-CoV and NL63 S proteins,
that is, that SARS-CoV S protein has a significantly higher
affinity for ACE-2 thanNL63 S protein, but that multivalency
partly reduces the factor of difference. Densitometry of the
pull-downsrevealeda.10-folddifferencein solution(Fig. 2),
while peak fluorescence showed an approximately threefold
difference at the cell surface (Fig. 3). We speculate that while
NL63 can use ACE-2 as a receptor for virus entry almost as
effectively as SARS-CoV, the consequence of binding on
events downstream of ACE-2 binding may be different. This
is consistent with the relative levels of cell entry exhibited by
viruses pseudotyped by SARS-CoV S and NL63 S (SARS-
CoV.NL63) (Hofmann et al., 2006); however, a soluble
purified RBD of SARS-CoV S was a relatively weak
competitor for NL63 S-mediated pseudotype virus entry (Li
et al., 2007). In addition, we confirmed that ACE-2 residues
key to SARS-CoV S binding are also involved in NL63
binding but that the contribution of individual residues,
exemplified here by K353A, may differ. This will relate to the
molecular contact between S protein and the receptor, which
has been described for SARS-CoV but remains unknown in
NL63 (Li et al., 2005a), despite the identification of residues
critical for contact (Lin et al.,2 0 0 8 ) .I tr e m a i n st ob e
determined exactly what difference in ACE-2 signalling, if
any, follows SARS-CoV and NL63 S protein binding and
whether this relates to the pathology of infection.
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